Thompson Investment Management Inc. Sells 19,615 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Thompson Investment Management Inc. decreased its position in Bausch Health Companies Inc. (NYSE:BHC) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 243,147 shares of the company’s stock after selling 19,615 shares during the quarter. Thompson Investment Management Inc.’s holdings in Bausch Health Companies were worth $1,960,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Tobam grew its position in Bausch Health Companies by 10.4% during the fourth quarter. Tobam now owns 15,034 shares of the company’s stock valued at $121,000 after buying an additional 1,422 shares during the period. DGS Capital Management LLC bought a new position in Bausch Health Companies during the fourth quarter valued at about $143,000. International Assets Investment Management LLC bought a new position in Bausch Health Companies during the third quarter valued at about $1,910,000. Merit Financial Group LLC bought a new position in Bausch Health Companies during the fourth quarter valued at about $228,000. Finally, Sanders Morris Harris LLC grew its position in Bausch Health Companies by 16.0% during the fourth quarter. Sanders Morris Harris LLC now owns 28,975 shares of the company’s stock valued at $234,000 after buying an additional 4,000 shares during the period. Institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Price Performance

Shares of NYSE BHC opened at $6.45 on Friday. Bausch Health Companies Inc. has a one year low of $3.96 and a one year high of $11.46. The firm’s 50 day simple moving average is $7.65 and its two-hundred day simple moving average is $7.44. The stock has a market capitalization of $2.33 billion, a P/E ratio of -13.43, a PEG ratio of 0.34 and a beta of 0.68.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. StockNews.com raised shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Jefferies Financial Group reissued a “hold” rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a report on Thursday. Finally, Royal Bank of Canada lowered their target price on shares of Bausch Health Companies from $11.00 to $10.00 and set a “sector perform” rating on the stock in a research note on Thursday, January 30th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $7.42.

Bausch Health Companies Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.